In last trading session, Taysha Gene Therapies Inc (NASDAQ:TSHA) saw 4.8 million shares changing hands with its beta currently measuring 0.68. Company’s recent per share price level of $3.00 trading at $0.07 or 2.39% at ring of the bell on the day assigns it a market valuation of $629.52M. That closing price of TSHA’s stock is at a discount of -44.0% from its 52-week high price of $4.32 and is indicating a premium of 60.33% from its 52-week low price of $1.19. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 7.58 million shares which gives us an average trading volume of 3.60 million if we extend that period to 3-months.
For Taysha Gene Therapies Inc (TSHA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.09. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Upright in the green during last session for gaining 2.39%, in the last five days TSHA remained trading in the green while hitting it’s week-highest on Wednesday, 11/27/24 when the stock touched $3.00 price level, adding 5.96% to its value on the day. Taysha Gene Therapies Inc’s shares saw a change of 69.49% in year-to-date performance and have moved 49.25% in past 5-day. Taysha Gene Therapies Inc (NASDAQ:TSHA) showed a performance of 59.57% in past 30-days. Number of shares sold short was 15.75 million shares which calculate 3.05 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8.5 to the stock, which implies a rise of 64.71% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 44. It follows that stock’s current price would drop -66.67% in reaching the projected high whereas dropping to the targeted low would mean a loss of -66.67% for stock’s current value.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
Statistics highlight that Taysha Gene Therapies Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -4.15% of value to its shares in past 6 months, showing an annual growth rate of 63.54% while that of industry is 24.80. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -46.63% from the last financial year’s standing.
11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 2.05M for the same. And 8 analysts are in estimates of company making revenue of 1.49M in the next quarter. Company posted 3.6M and 3.41M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -137.69% during past 5 years.
Taysha Gene Therapies Inc (NASDAQ:TSHA)’s Major holders
Insiders are in possession of 17.54% of company’s total shares while institution are holding 77.46 percent of that, with stock having share float percentage of 93.93%. Investors also watch the number of corporate investors in a company very closely, which is 77.46% institutions for Taysha Gene Therapies Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at TSHA for having 21.21 million shares of worth $47.51 million. And as of 2024-06-30, it was holding 9.1722 of the company’s outstanding shares.
The second largest institutional holder is RTW INVESTMENTS, LP, which was holding about 18.8 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.1299 of outstanding shares, having a total worth of $42.11 million.
On the other hand, Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 4.72 shares of worth $14.17 million or 2.30% of the total outstanding shares. The later fund manager was in possession of 4.46 shares on Jun 30, 2024 , making its stake of worth around $13.37 million in the company or a holder of 2.17% of company’s stock.
